biostudies-literatureBalbach MLNCI NIH HHSNational Comprehensive Cancer Network100306https://www.ebi.ac.uk/biostudies/studies/S-EPMC9010630biostudies-literatureUnknown3(5)The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously "undruggable" target. Here, we present the second reported case of de novo <i>KRAS</i> G12C-mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?JTO clinical and research reportsDe Novo <i>KRAS</i> G12C-Mutant SCLC: A Case Report.PMC9010630K12 CA090625030763Eisenberg RBalbach MLIams WTfalseDe Novo <i>KRAS</i> G12C-Mutant SCLC: A Case Report.The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously "undruggable" target. Here, we present the second reported case of de novo <i>KRAS</i> G12C-mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?2022-01-01T00:00:00Z2022 May2025-04-04T19:31:56.906Z2025-02-19T02:58:41.347ZS-EPMC90106303543466710.1016/j.jtocrr.2022.100306